# Michael Nauck

I migliori episodi di podcast
Aggiornato:

The Lancet Diabetes & Endocrinology: November 14, 2013

Michael Nauck discusses incretin-based drugs and pancreatitis risk.

The Lancet Diabetes & Endocrinology: November 14, 2013

Michael Nauck discusses incretin-based drugs and pancreatitis risk.

MDT and patient perspectives on the role of GLP-1 RAs in the T2D management pathway

touchMDT for touchENDOCRINOLOGY Listen to key experts from a multidisciplinary team and a patient explore the role of GLP-1 RAs in the T2D management pathway, real-world factors affecting selection of a GLP-1 RA, and how GLP-1 RA therapy has influenced real-life patients in their glycemic and weig…

MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D

touchMDT for touchENDOCRINOLOGY Listen to key experts from a multidisciplinary team review the rationale for using GLP-1 as a therapeutic target in T2D and provide an overview of GLP-1 RA based therapies  The multidisciplinary team Primary Care Physician: Dr Kevin Fernando, Berwick, UK Endocri…

Bonus Episode: Incretin Hormones and Their Role in Glucose Regulation and Type 2 Diabetes

In this episode, the experts dive deeper into the mechanisms and physiological targets through which incretin hormones work (GLP-1), ensuring the harmonious balance of glucose metabolism and appetite regulation. They explore the intricate molecular pathways and unveil the physiological effects th…

Bonus Episode: Exploring the Clinical Benefits and Therapeutic Approaches for Managing Type 2 Diabetes

In this episode, the experts focus on incretin hormones, their clinical benefits, and therapeutic approaches, providing valuable insights into incretin-based therapies, and the perspectives of the EASD-ADA guidelines and when it is clinically appropriate to start prescribing incretins for blood…

Bonus Episode: Patient Perspectives of Managing Type 2 Diabetes

In this final episode, the experts consider the patient perspective of managing type 2 diabetes and its complications while tailoring treatment approaches to individual characteristics. They also consider the patient's needs with a focus towards incretin/gut hormones and providing practical insig…

The Rise of GIP: From Biology to Medicine

Delve into the evolving story of GIP-based therapies and their role in type 2 diabetes care. In this episode, our expert guests explore how dual and triple agonists like tirzepatide are reshaping obesity and metabolic control, and why GIP is gaining renewed attention in diabetes pharmacology. You …

Dr. Michael Nauck: GLP-1 Origins | Ep. 02

In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expand…

Lois Donovan on Intrapartum/Early Postpartum use of Automated Insulin Delivery, Michael Nauk on the Potential of GIP in T2D & Obesity, and more!

Welcome to the latest episode (August 2026) of Diabetes Care "On Air"—a new and different way to bring the research published in Diabetes Care to life. Join co-hosts Alice Cheng, MD, FRCPC, and Michael Rickels, MD, MS, as they discuss the latest and greatest content in the August 2026 issue of Diab…